Efficiency of Atorvastatin in the Protection of Anthracycline-Induced Cardiomyopathy

Abstract

LVEF ϭ left ventricular ejection fraction; LVEDD ϭ left ventricular end-diastolic diameter; LVESD ϭ left ventricular end-systolic diameter.

Myocardial Protection During Cardiotoxic Chemotherapy

“…76 Finally, a study has recently reported the preventive effects of spironolactone on anthracycline-induced myocardial toxicity in patients with breast cancer. 77 Important limitations of all of these studies [67][68][69][70][71][72][73][74][75][76][77][78] include the small number of patients treated, differences in study design, varying malignancies being studied and chemotherapy regimens used, and short follow-up times. In addition, in most studies, the mortality rate was lower than expected, and the reported beneficial effects on the incidence of HF and LVEF decline did not translate to lower mortality ( Table 2).…”

Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

“…189 The most effective agents appear to be dexrazoxane 190,191 and statin therapy. 192,193 The use of vasoactive medications may be limited by the risk for side effects (especially dizziness and hypotension) 194 and is supported by limited evidence for angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and b-blockers. [195][196][197][198][199] Given the frequency of asymptomatic LV dysfunction and the potential side effects associated with the proposed regimens, early identification and treatment may be the optimal path.…”

Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection

“…Retrospective observational studies showed reduction in hospitalization for HF in breast cancer patients co-treated with anthracyclines and statins [62]. In a small study of 40 patients treated with anthracyclines and randomized into statin group or control group, atorvastatin showed significant improvement of left ventricular ejection fraction as compared to control group [63].…”